UCB Pharma has agreed to acquire a 51% majority stake in privately held Meizler Biopharma in order to make a direct entry into the Brazilian pharmaceutical market. Although the specific financial details of the transaction were not disclosed, Meizler’s owners are entitled to performance-related milestone payments and UCB has an option to purchase the remaining 49% in the future. The deal is the latest example of a global pharmaceutical company targeting Brazil for expansion.